1
|
Parry H, McIlroy G, Bruton R, Damery S, Tyson G, Logan N, Davis C, Willett B, Zuo J, Ali M, Kaur M, Stephens C, Brant D, Otter A, McSkeane T, Rolfe H, Faustini S, Richter A, Lee S, Wandroo F, Shafeek S, Pratt G, Paneesha S, Moss P. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. J Hematol Oncol 2022; 15:3. [PMID: 35000597 PMCID: PMC8743056 DOI: 10.1186/s13045-021-01219-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 12/03/2021] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Immune suppression is a clinical feature of chronic lymphocytic leukaemia (CLL), and patients show increased vulnerability to SARS-CoV-2 infection and suboptimal antibody responses. METHOD We studied antibody responses in 500 patients following dual COVID-19 vaccination to assess the magnitude, correlates of response, stability and functional activity of the spike-specific antibody response with two different vaccine platforms. RESULTS Spike-specific seroconversion post-vaccine was seen in 67% of patients compared to 100% of age-matched controls. Amongst responders, titres were 3.7 times lower than the control group. Antibody responses showed a 33% fall over the next 4 months. The use of an mRNA (n = 204) or adenovirus-based (n = 296) vaccine platform did not impact on antibody response. Male gender, BTKi therapy, prophylactic antibiotics use and low serum IgA/IgM were predictive of failure to respond. Antibody responses after CD20-targeted immunotherapy recovered 12 months post treatment. Post-vaccine sera from CLL patients with Spike-specific antibody response showed markedly reduced neutralisation of the SARS-CoV-2 delta variant compared to healthy controls. Patients with previous natural SARS-CoV-2 infection showed equivalent antibody levels and function as healthy donors after vaccination. CONCLUSIONS These findings demonstrate impaired antibody responses following dual COVID-19 vaccination in patients with CLL and further define patient risk groups. Furthermore, humoural protection against the globally dominant delta variant is markedly impaired in CLL patients and indicates the need for further optimisation of immune protection in this patient cohort.
Collapse
Affiliation(s)
- Helen Parry
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Graham McIlroy
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - Rachel Bruton
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Sarah Damery
- Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK
| | - Grace Tyson
- MRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
| | | | - Chris Davis
- MRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
| | - Brian Willett
- MRC- University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, G61 1QH, UK
| | - Jianmin Zuo
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Myah Ali
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Manjit Kaur
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Christine Stephens
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Dawn Brant
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Ashley Otter
- UK Health Security Agency, Porton Down, Salisbury, SP4 OJG, UK
| | - Tina McSkeane
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK
| | - Hayley Rolfe
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK
| | - Sian Faustini
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Alex Richter
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - Sophie Lee
- Department of Haematology, The Royal Wolverhampton NHS Trust. Wolverhampton Hospital, Wolverhampton, WV10 0QP, UK
| | - Farooq Wandroo
- Department of Haematology. Sandwell and West Birmingham, NHS Trust, Birmingham, B18 7QH, UK
| | - Salim Shafeek
- Department of Haematology, Worcestershire Acute Hospitals NHS Trust, Worcester, WR5 1DD, UK
| | - Guy Pratt
- Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2TH, UK
| | - Shankara Paneesha
- Birmingham Heartlands Hospital, University Hospitals Birmingham, Birmingham, B9 5SS, UK
| | - Paul Moss
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
| |
Collapse
|
2
|
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, Otter A, McSkeane T, Rolfe H, Faustini S, Wall N, Hillmen P, Pratt G, Paneesha S, Zuo J, Richter A, Moss P. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J 2021; 11:136. [PMID: 34330895 PMCID: PMC8323747 DOI: 10.1038/s41408-021-00528-x] [Citation(s) in RCA: 67] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 07/05/2021] [Accepted: 07/09/2021] [Indexed: 12/15/2022] Open
Abstract
B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection against severe infection but relatively little is known regarding the profile of the antibody response following first or second vaccination. We studied spike-specific antibody responses following first and/or second Covid-19 vaccination in 299 patients with CLL compared with healthy donors. 286 patients underwent extended interval (10-12 week) vaccination. 154 patients received the BNT162b2 mRNA vaccine and 145 patients received ChAdOx1. Blood samples were taken either by venepuncture or as dried blood spots on filter paper. Spike-specific antibody responses were detectable in 34% of patients with CLL after one vaccine (n = 267) compared to 94% in healthy donors with antibody titres 104-fold lower in the patient group. Antibody responses increased to 75% after second vaccine (n = 55), compared to 100% in healthy donors, although titres remained lower. Multivariate analysis showed that current treatment with BTK inhibitors or IgA deficiency were independently associated with failure to generate an antibody response after the second vaccine. This work supports the need for optimisation of vaccination strategy in patients with CLL including the potential utility of booster vaccines.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Viral/blood
- Antibodies, Viral/immunology
- Antibody Formation/drug effects
- BNT162 Vaccine
- COVID-19/blood
- COVID-19/immunology
- COVID-19/prevention & control
- COVID-19 Vaccines/administration & dosage
- COVID-19 Vaccines/immunology
- Female
- Humans
- Immunization, Secondary
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Male
- Middle Aged
Collapse
Affiliation(s)
- H Parry
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - G McIlroy
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK
| | - R Bruton
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - M Ali
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - C Stephens
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - S Damery
- Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK
| | - A Otter
- National infection Service, Public Health England, Porton Down, Salisbury, SP4 OJG, UK
| | - T McSkeane
- Cancer Research UK Clinical Trials Unit, University of Birmingham, B15 2TT, Birmingham, UK
| | - H Rolfe
- Cancer Research UK Clinical Trials Unit, University of Birmingham, B15 2TT, Birmingham, UK
| | - S Faustini
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - N Wall
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - P Hillmen
- St. James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, UK
| | - G Pratt
- Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2TH, UK
| | - S Paneesha
- Birmingham Heartlands Hospital, University Hospitals Birmingham, Bordesley Green East, B9 5SS, Birmingham, UK
| | - J Zuo
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - A Richter
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK
| | - P Moss
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, B15 2TT, UK.
- Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2TH, UK.
| |
Collapse
|
4
|
Brannigan A, Williams NN, Grahn M, Williams NS, Fitzpatrick JM, O’Connell PR, Soong CV, Blair P, Halliday MI, Hood JM, Rowlands BJ, D’sa AABB, Cahill RJ, Beattie S, Hamilton H, O’Morain C, Kelly SJ, O’Malley KE, Stack WA, O’Donoghue D, Baird AW, Cronin KJ, Kerin MJ, Crowe J, MacMathuna P, Lennon J, Gorey TF, Chua A, O’Kane V, Dinan TG, Keeling PWN, Mulligan E, Cronin KL, Dervan P, Ireland A, Murphy D, O’Sullivan G, Ryan E, Kelly P, Gilvarry J, Sant S, Fan XJ, Chua A, Shahi CN, O’Connell M, Weir DG, Kelleher D, McDevitt J, O’Donoghue JM, Horgan PG, Byrne WJ, McGuire M, Given HF, Daw MA, Kavanagh P, O’Mahony P, Joy T, Gleeson F, Mullan A, Gibney M, Mannion A, Stevens FM, McCarthy CF, Killeen AA, Murchan PM, Reynolds JV, Leonard N, Marks P, Keane FBV, Tanner WA, O’Connell MA, Corridan B, Collins R, Shannon R, Cahill R, Joyce WP, Goggin M, O’Donoghue D, Hyland J, Traynor O, Qureshi A, DaCosta M, Brindley N, Burke P, Grace P, Bouchier-Hayes D, Leahy AL, Courtney G, Osbome H, O’Donovan N, O’Donoghue M, Collins JK, Morrissey D, McCarthy JE, Redmond HP, Hill ADK, Grace PA, Naama H, Austin OM, Bouchier-Hayes DM, Daly JM, Mulligan E, Fitzpatrick JM, Breslin D, Delaney CP, O’Sullivan ST, O’Sullivan GC, Kirwan WO, Weir CD, McGrath LT, Maynard S, Anderson NH, Halliday MI, D’sa AABB, Gokulan C, O’Gorman TA, Breshihan E, Lam PY, Skehill R, Grimes H, McKeever JA, Stokes MA, Mehigan D, Keaveny TV, Meehan J, Molloy A, Q’Farrelly C, Scott J, Dudeney MS, Leahy A, Grace. PA, McEntee G, Hcaton ND, Douglas V, Mondragon R, O’Grady J, Williams R, Tan KC, Xia HX, Keane CT, O’Morain CA, O’Mahony A, O’Sullivan GC, Corbett A, O’Mahony A, Ireland A, Harte P, Mulcahy H, Patchett S, Stack W, Gallagher M, Connolly K, Doyle J, Flynn JR, Maher M, Hehir D, Horgan A, Stuart R, Brady MP, Johnston PW, Johnston BT, Collins BJ, Collins JSA, Love AHG, Marshall SG, Parks TG, Spence RAJ, O’Connor HJ, Cunnane K, Duggan M, MacMalhuna P, Delaney CP, Kerin M, Gorey TF, Attwood SEA, Viani L, Jeffers M, Walsh TN, Byrne PJ, Frazer I, Hennessy TPJ, Hill GL, Dickey W, McMillan SA, Bharucha C, Porter KG, Rolfe H, Thornton J, Attwood SEA, Coleman J, Stephens RB, Hone S, Holmes K, Kelly IP, Corrigan TP, McCrory D, McCaigue M, Barclay GR, Stack WA, Quirke M, Hegarty JE, O’Donoghue DP, O’Hanlon D, Byrne J. Irish society of gastroenterology. Ir J Med Sci 1992. [DOI: 10.1007/bf02942367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|